Abstracts (HTML) List of Authors

van Ewijk, R

SEAL program – Early detection of liver fibrosis and cirrhosis by screening of the general population

Vaquero, J

Shedding light on BASH: A novel experimental model of advanced liver damage

Vehreschild, MJG

Phenotyping non-alcoholic fatty liver disease by the gut microbiota – ready for prime time?

Velthuis, L

SEAL program – Early detection of liver fibrosis and cirrhosis by screening of the general population

Verheij, J

Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities

Vermehren, J

Evaluation of a piglet model for Parenteral Nutrition-associated Cholestasis (PNAC)

Villa, M

Metabolic programming of exhausted CD8+ T cells in chronic viral hepatitis

Vogel, A

Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities
Retrospektive Analyse des Therapieerfolgs von TIPS Anlagen und Identifikation prognostischer Parameter hierfür
Growth differentiation factor 11 mitigates liver fibrosis via expansion of liver progenitor cells

Vogel, MN

HER2 amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis

Vogg, J

Correlation of Liver Perfusion with Outcome of Patients with Severe Liver Disease – A Prospective Cohort Study

Vogt, M

Glucose and metformin differentially regulate FGF19 signaling in human HepG2 cells

Vohlen, C

Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming

Voitl, R

Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis

Volckmar, AL

Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities

Volz, T

Both interferon and siRNA treatments promote reappearance of SMC5/6 complex but have different impact on cccDNA

Vorhauer, L

Expression and function of Epithelial Splicing Regulatory Protein 1 in hepatocellular carcinoma

Vorokova, N

Safety and Efficacy of 10 mg Myrcludex B/IFNa Combination Therapy in Patients with Chronic HBV/HDV Co-Infection

Voß, J

Europäische Studie: Heterozygoter Alpha-1-Antitrypsinmangel (Pi*MZ) führt zu einem intermediären Leber-Phänotyp

Voswinckel, R

Fibrocytes contribute to TAA-induced liver fibrosis in mice

Vucur, M

RIPK1 and MLKL in hepatocytes do not mediate Concanavalin A (ConA)-mediated liver toxicity
NEMO prevents hepatocarcinogenesis independently of an IKK complex function by controlling liver regeneration